Matthew Mishan analyst KEYBANK

Currently, out of the existing stock ratings of Matthew Mishan - 6 which are a Hold (3.97%), 145 which are a Buy (96.03%)

Matthew Mishan

Work Performance Price Targets & Ratings Chart

Analyst Matthew Mishan works at KEYBANK and is covering Healthcare, Basic Materials sectors with 296 price targets and ratings displayed on 19 stocks.

Matthew Mishan's average stock forecast success ratio is 57.19% with an average time for price targets to be met of 164.21 days.

Most recent stock forecast was given on AGTI, Agiliti at 09-Aug-2023.

Wall Street Analyst Matthew Mishan

Analyst best performing recommendations are on PRCT.
The best stock recommendation documented was for ITGR (INTEGER HOLDINGS) at 4/29/2021. The price target of $94 was fulfilled within 1 day with a profit of $1.16 (1.22%) receiving and performance score of 12.19.

Average potential price target upside

AGTI Agiliti AVNS Avanos Medical BAX Baxter International BDX Becton, Dickinson and Company HRC HillRom Holdings ICUI ICU Medical ITGR Integer Holdings RMD ResMed STE STERIS plc TFX Teleflex ANGO AngioDynamics COO The Cooper Companies CTLT Catalent INGN Inogen SHC Sotera Health Company AVTR Avantor INSP Inspire Medical Systems PKI PerkinElmer PRCT

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

10

$1.59 (18.91%)

16

22 days ago

1/3 (33.33%)

$2.96 (29.68%)

44

Buy

13

$6.51 (100.31%)

28

3 months 21 days ago

1/3 (33.33%)

$4.47 (25.29%)

17

Buy

20

3 months 26 days ago

1/6 (16.67%)

$4.39 (22.79%)

48

Buy

20

$11.59 (137.81%)

23

3 months 27 days ago

1/5 (20%)

$6.31 (40.38%)

25

Hold

18

$9.59 (114.03%)

19

3 months 27 days ago

1/2 (50%)

$3.94 (29.73%)

49

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Matthew Mishan is most bullish on?

Potential upside of $99.05 has been obtained for RMD (RESMED)

Which stock is Matthew Mishan is most reserved on?

Potential downside of -$0 has been obtained for AVNS (AVANOS MEDICAL)

What Year was the first public recommendation made by Matthew Mishan?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

How to use the chart